While no studies to date have documented EP300 mutations specifically in DS-ALL, epigenetic regulators such as EP300 and CREBBP are recurrently altered in pediatric ALL and have been implicated in treatment resistance and transcriptional dysregulation. Here, EP300 is linked to acute lymphoblastic leukemia.